Chromosome translocation frequency after radioiodine thyroid remnant ablation: A comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 9, 2009, Pages 3472-3476

  Frigo, Anna ^a   Dardano, Angela ^b   Danese, Elisa ^a   Davì, Maria Vittoria ^a   Moghetti, Paolo ^a   Colato, Chiara ^a   Francia, Giuseppe ^a   Bernardi, Franca ^a   Traino, Claudio ^c   Monzani, Fabio ^b   Ferdeghini, Marco ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; LIOTRIX; RECOMBINANT THYROTROPIN;

ADULT; ARTICLE; CHROMOSOME 1; CHROMOSOME 4; CHROMOSOME 8; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIATED THYROID CARCINOMA; DRUG ACTIVITY; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FREQUENCY; GENE TRANSLOCATION; HUMAN; MALE; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; THYROID CARCINOMA;

EID: 69949091536     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2830     Document Type: Article

References (20)

1. Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, Lind P, Limbert E, Jarzab B, Jamar F, Duntas L, Cohen O, Berg G 2004 Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 151:539-548 (Pubitemid 39562507)
2. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932 (Pubitemid 43357760)
3. 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal. Nucl Med Commun 28:215-223
4. 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 49:1445-1450
5. Ramírez MJ, Surrallés J, Galofré P, Creus A, Marcos R 1997 Radioactive iodine induces clastogenic and age-dependent aneugenic effects in lymphocytes of thyroid cancer patients as revealed by interphase FISH. Mutagenesis 12:449-455 (Pubitemid 27503900)
6. Ballardin M, Barsacchi R, Bodei L, Caraccio N, Cristofani R, Di Martino F, Ferdeghini M, Kusmic C, Madeddu G, Monzani F, Rossi AM, Sbrana I, Spanu A, Traino C, Barale R 2004 Oxidative and genotoxic damage after radio-iodine therapy of Graves' hyperthyroidism. Int J Radiat Biol 80:209-216 (Pubitemid 38586330)
7. Dardano A, Ballardin M, Ferdeghini M, Lazzeri E, Traino C, Caraccio N, Mariani G, Barale R, Monzani F 2007 Anticlastogenic effect of Ginkgo biloba extract in Graves' disease patients receiving radioiodine therapy. J Clin Endocrinol Metab 92:4286-4289
8. de Vathaire F 2008 The carcinogenic effects of radioiodine therapy for thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:180-181
9. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504-515 (Pubitemid 351240823)
10. Sobin LH, Wittekind CH 2002 TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss
11. Wolfram RM, Palumbo B, Chehne F, Palumbo R, Budinsky AC, Sinzinger H 2004 (Iso) Prostaglandins in saliva indicate oxidation injury after radioiodine therapy. Rev Esp Med Nucl 23:183-188 (Pubitemid 39456459)
12. Léonard A, Rueff J, Gerber GB, Léonard ED 2005 Usefulness and limits of biological dosimetry based on cytogenetic methods. Radiat Prot Dosimetry 115:448-454
13. Puerto S, Marcos R, Ramírez MJ, Galofré P, Creus A, Surrallés J 2000 Equal induction and persistence of chromosome aberrations involving chromosomes 1, 4 and 10 in thyroid cancer patients treated with radioactive iodine. Mutat Res 469:147-158 (Pubitemid 30628683)
14. Whitehouse CA, Edwards AA, Tawn EJ, Stephan G, Oestreicher U, Moquet JE, Lloyd DC, Roy L, Voisin P, Lindholm C, Barquinero J, Barrios L, Caballin MR, Darroudi F, Fomina J 2005 Translocation yields in peripheral blood lymphocytes from control populations. Int J Radiat Biol 81:139-145 (Pubitemid 40839857)
15. M'Kacher R, Legal JD, Schlumberger M, Voisin P, Aubert B, Gaillard N, Parmentier C 1996 Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma. J Nucl Med 37:1860-1864 (Pubitemid 26378380)
16. Lambert V, Thierens H, Monsieurs M, Roncancio C, Laurent C 2001 Translocation frequencies measured in patients one year after radioactive iodine therapy for thyrotoxicosis. Int J Radiat Biol 77:679-685 (Pubitemid 32531884)
17. Wokolorczyk D, Gliniewicz B, Sikorski A, Zlowocka E, Masojc B, Debniak T, Matyjasik J, Mierzejewski M, Medrek K, Oszutowska D, Suchy J, Gronwald J, Teodorczyk U, Huzarski T, Byrski T, Jakubowska A, Górski B, van de Wetering T, Walczak S, Narod SA, Lubinski J, Cybulski C 2008 A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res 68:9982-9986
18. Luomahaara S, Lindholm C, Mustonen R, Salomaa S 1999 Distribution of radiation-induced exchange aberrations in human chromosomes 1, 2 and 4. Int J Radiat Biol 75:1551-1556
19. de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJ, de Klerk JM 2004 Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med 45:1549-1554 (Pubitemid 47618509)
20. M'Kacher R, Légal JD, Schlumberger M, Aubert B, Beron-Gaillard N, Gaussen A, Parmentier C 1997 Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma. J Nucl Med 38:377-380 (Pubitemid 27376887)